# Albumin Binding siRNAs for Systemic Treatment of Multi-Joint Osteoarthritis

> **NIH NIH R21** · VANDERBILT UNIVERSITY · 2022 · $204,011

## Abstract

Project Summary / Abstract
Osteoarthritis (OA) is a chronic degenerative disease that affects joints and their surrounding tissues. OA can
occur spontaneously with aging or be secondary to injury in the case of post-traumatic osteoarthritis (PTOA).
OA/PTOA causes significant morbidity and loss of quality of life, resulting in an estimated financial burden in
the U.S. of over $44 billion annually. Non-steroidal anti-inflammatory drugs are typically the first line of
treatment to deal with pain but do not slow cartilage deterioration and can cause gastrointestinal problems. The
Osteoarthritis Research Society International recommends corticosteroids for temporary pain relief, but
steroids also do not target the underlying cause of disease and may even worsen cartilage thinning. These
shortcomings leave an unmet need for disease-modifying OA/PTOA drugs (DMOADs) that block or reduce
disease progression. In OA/PTOA, synoviocytes and chondrocytes produce inflammatory cytokines and
matrix metalloproteinases (MMPs) that drive the joint degenerative process. Small molecule MMP inhibitors
have been tested clinically for cancer but failed largely due to systemic toxicities caused by the lack of MMP
selectivity. RNA interference is a promising strategy for creation of target selective therapeutics against
difficult to drug molecular targets. This project is focused on development and PTOA therapeutic testing of
siRNA therapeutics that can selectively inhibit specific collagenases, either alone or in combination. The
proposed approach builds from our recent work developing siRNA molecules end-modified through a PEG
linker with a diacyl lipid (siRNA-L2), which spontaneously forms a molecular complex with albumin (alb/
siRNA-L2) in situ following intravenous injection. This albumin “hitchhiking” siRNA-L2 enhances siRNA PK, is
very safe, and increases level and homogeneity of delivery, particularly to tissues characterized by
inflammation and vascular leakiness. The overall goal of this proposal is to implement siRNA-L2 to
systemically treat and block progression of PTOA. This project will assess siRNA-L2 therapeutic index in a
PTOA mouse model and then test the disease efficacy of targeting single versus multiple proteases in a guinea
pig PTOA model.

## Key facts

- **NIH application ID:** 10358582
- **Project number:** 5R21AR078636-02
- **Recipient organization:** VANDERBILT UNIVERSITY
- **Principal Investigator:** Craig Lewis Duvall
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $204,011
- **Award type:** 5
- **Project period:** 2021-02-19 → 2024-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10358582

## Citation

> US National Institutes of Health, RePORTER application 10358582, Albumin Binding siRNAs for Systemic Treatment of Multi-Joint Osteoarthritis (5R21AR078636-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10358582. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*